|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13,710.00 GBX | +0.57% |
|
+1.54% | -0.58% |
MarketScreener Strategies
Search
 | AstraZeneca: Desirable start to 2026, but most strengths are already priced in | April 29, 2026 at 09:18 am EDT |
| AstraZeneca: Strengths remain aptly valued | March 06, 2026 at 12:58 pm EST |
 | AstraZeneca: Bright 2026 outlook a key takeaway | February 10, 2026 at 12:01 pm EST |
| AstraZeneca benefits from oncology momentum but valuation limits upside | November 19, 2025 at 07:43 am EST |
| AstraZeneca delivers Q3 earnings beat but upside looks limited | November 06, 2025 at 10:14 am EST |
 | AstraZeneca's CEO reportedly considers listing in the United States | July 02, 2025 at 03:39 am EDT |
No results for this search
Filters
Headlines
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- MarketScreener Strategies
Select your edition
All financial news and data tailored to specific country editions
